Markiewicz-Gospodarek Agnieszka, Markiewicz Renata, Dobrowolska Beata, Maciejewski Ryszard, Łoza Bartosz
Department of Human Anatomy, Medical University of Lublin, 20-090 Lublin, Poland.
Department of Neurology, Neurological and Psychiatric Nursing, Medical University of Lublin, 20-093 Lublin, Poland.
Brain Sci. 2022 Jun 11;12(6):768. doi: 10.3390/brainsci12060768.
Neuropeptide S (NPS) is a factor associated with the central regulation of body weight, stress, anxiety, learning, memory consolidation, wakefulness-sleep cycle, and anti-inflammatory and neuroplastic effects. Its stress-reducing, anti-anxiety, arousal without anxiety, and pro-cognitive effects represent an interesting option for the treatment of neuropsychiatric disorders. The purpose of the study was to examine the potential associations of NPS levels in the blood with clinical and metabolic parameters during the rehabilitation therapy of patients with schizophrenia. Thirty-three male subjects diagnosed with schizophrenia were randomly divided into two groups. The rehabilitation group (REH, N16) consisted of patients who were subjected to structured, 3-month intensive rehabilitation therapy, and the control group (CON, N17) consisted of patients who were subjected to a standard support mechanism. Both groups continued their pharmacological treatment as usual. The NPS concentration, as well as clinical and metabolic parameters, were compared in both groups. Additionally, a group of healthy (H) males (N15) was tested for NPS reference scores. To look for the specificity and selectivity of the NPS relationship with clinical results, various factor models of the positive and negative syndrome scale (PANSS) were analyzed, including the original PANSS 2/3 model, its modified four-factor version, the male-specific four-factor model, and two five-factorial models validated in large groups in clinical and multi-ethnic studies. Results and conclusions: (1) Structured rehabilitation therapy, compared to unstructured supportive therapy, significantly reduced the level of schizophrenia disorders defined by various factor models derived from PANSS. (2) The clinical improvement within the 3-month rehabilitation therapy course was correlated with a significant decrease in neuropeptide S (NPS) serum level. (3) The excitement/Hostility (E/H) factor, which included schizophrenic symptoms of the psychotic disorganization, was specific and selective for the reduction in serum NPS, which was stable across all analyzed factor models. (4) The long-term relationship between serum NPS and clinical factors was not accompanied by basic metabolic parameters.
神经肽 S(NPS)是一种与体重、应激、焦虑、学习、记忆巩固、觉醒-睡眠周期以及抗炎和神经可塑性效应的中枢调节相关的因子。其减轻应激、抗焦虑、无焦虑唤醒和促认知效应代表了治疗神经精神疾病的一个有趣选择。本研究的目的是在精神分裂症患者康复治疗期间,研究血液中 NPS 水平与临床和代谢参数之间的潜在关联。33 名被诊断为精神分裂症的男性受试者被随机分为两组。康复组(REH,N = 16)由接受为期 3 个月结构化强化康复治疗的患者组成,对照组(CON,N = 17)由接受标准支持机制的患者组成。两组均照常继续其药物治疗。比较两组的 NPS 浓度以及临床和代谢参数。此外,对一组健康(H)男性(N = 15)进行 NPS 参考评分测试。为了寻找 NPS 与临床结果关系的特异性和选择性,分析了阳性和阴性症状量表(PANSS)的各种因子模型,包括原始的 PANSS 2/3 模型、其改良的四因子版本、男性特异性四因子模型以及在临床和多民族研究的大组中验证的两个五因子模型。结果与结论:(1)与非结构化支持治疗相比,结构化康复治疗显著降低了由 PANSS 衍生的各种因子模型所定义的精神分裂症障碍水平。(2)在 3 个月康复治疗过程中的临床改善与神经肽 S(NPS)血清水平的显著降低相关。(3)包括精神分裂症性紊乱精神症状的兴奋/敌意(E/H)因子对血清 NPS 的降低具有特异性和选择性,在所有分析的因子模型中均稳定。(4)血清 NPS 与临床因子之间的长期关系未伴有基本代谢参数。